Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

I-Mab to Concentrate on Five Clinical-Stage Candidates, Will Out-license International Rights

publication date: Aug 30, 2022

I-Mab said it would concentrate its drug development efforts on five key candidates, for which it will seek international partners once the candidates show Phase I or II proof of concept. It plans to out-license ex-China rights, while retaining China rights, though it will also partner commercialization in China to avoid the cost of building a sales force. The detailed presentation of the company’s assets seems an oblique denial that I-Mab is seeking to sell the entire company, a possibility raised in recent press reports. I-Mab pointed out that it has almost $600 million in cash, enough to support three years of operations. More details....

Stock Symbol: (NSDQ: IMAB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital